Skip to main content

Table 2 Multivariate analysis of recurrence-free survival in patients with stage I-III colon cancers

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

   Univariate HR
(95% CI)
Multivariate HR
(95% CI)
Age   1.015 (0.985-1.047) 1.028 (0.995-1.062)
Sex Male 1 (referent) 1 (referent)
  Female 1.438 (0.733-2.819) 1.600 (0.799-3.204)
Stage Stage I/II 1 (referent) 1 (referent)
  Stage III 2.303 (1.163-4.561) 2.587 (1.267-5.281)
Differentiation Well/Moderate 1 (referent) 1 (referent)
  Poor/Mucinous 1.210 (0.426-3.435) 1.347 (0.415-4.375)
CIMP CIMP-low/negative 1 (referent) 1 (referent)
  CIMP-high 0.523 (0.160-1.710) 0.806 (0.207-3.136)
MSI MSI-low/MSS 1 (referent) 1 (referent)
  MSI-high 0.394 (0.139-1.118) 0.485 (0.139-1.701)
BRAF mutation No 1 (referent) 1 (referent)
  Yes No recurrence No recurrence
KRAS mutation No 1 (referent) 1 (referent)
  Yes 1.096 (0.542-2.214) 1.185 (0.568-2.471)
MGMT methylation No 1 (referent) 1 (referent)
  Yes 0.667 (0.311-1.429) 0.703 (0.304-1.628)
  1. HR hazard ratio, CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stable